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Abstract
Background: Patients generally die of cancer after the failure of current therapies to eliminate residual disease. A
subpopulation of tumor cells, termed cancer stem cells (CSC), appears uniquely able to fuel the growth of phenotypically
and histologically diverse tumors. It has been proposed, therefore, that failure to effectively treat cancer may in part be due
to preferential resistance of these CSC to chemotherapeutic agents. The subpopulation of human colorectal tumor cells
with an ESA
+CD44
+ phenotype are uniquely responsible for tumorigenesis and have the capacity to generate
heterogeneous tumors in a xenograft setting (i.e. CoCSC). We hypothesized that if non-tumorigenic cells are more
susceptible to chemotherapeutic agents, then residual tumors might be expected to contain a higher frequency of CoCSC.
Methods and Findings: Xenogeneic tumors initiated with CoCSC were allowed to reach ,400 mm
3, at which point mice
were randomized and chemotherapeutic regimens involving cyclophosphamide or Irinotecan were initiated. Data from
individual tumor phenotypic analysis and serial transplants performed in limiting dilution show that residual tumors are
enriched for cells with the CoCSC phenotype and have increased tumorigenic cell frequency. Moreover, the inherent ability
of residual CoCSC to generate tumors appears preserved. Aldehyde dehydrogenase 1 gene expression and enzymatic
activity are elevated in CoCSC and using an in vitro culture system that maintains CoCSC as demonstrated by serial
transplants and lentiviral marking of single cell-derived clones, we further show that ALDH1 enzymatic activity is a major
mediator of resistance to cyclophosphamide: a classical chemotherapeutic agent.
Conclusions: CoCSC are enriched in colon tumors following chemotherapy and remain capable of rapidly regenerating
tumors from which they originated. By focusing on the biology of CoCSC, major resistance mechanisms to specific
chemotherapeutic agents can be attributed to specific genes, thereby suggesting avenues for improving cancer therapy.
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Introduction
The presence of diverse cell populations in normal and
neoplastic tissue has long been recognized. While normal tissue
structure and function is facilitated by diverse cell types, generated
during development and continually replaced to maintain
homeostasis, cancer is generally characterized by disorganized
overproliferation. Because genetic material is propagated over
extended periods of time due to the self-renewal properties of stem
cells, the compounding mutations required for tumorigenesis have
been hypothesized to arise in these rare cells and not their more
numerous progeny, which have a finite lifespan once committed to
differentiation. Like normal tissue-resident stem cells that support
the cellular hierarchy comprising a particular tissue over the
lifespan of an individual, cancer stem cells (CSC) are defined by
their ability to self-renew indefinitely, while maintaining their
ability to generate both tumorigenic (TG) and non-tumorigenic
(NTG) cells [1]. Unlike in normal development, however,
neoplastic progenitor cell populations can gain self-renewal
capabilities, thereby also fulfilling the definition of a CSC [2,3].
Ultimately, demonstration of the self-renewal and differentiation
capabilities that define a stem cell, both normal and neoplastic,
can be confirmed by serial transplant studies that enable
discrimination of cells possessing self-renewal ability versus those
capable of numerous, though finite, non self-renewing cell
divisions [4].
The CSC paradigm rests on the foundation that tumor
heterogeneity can be generated by a single CSC. Because
traditional cell lines and xenografts do not recapitulate the cellular
and morphological heterogeneity observed in xenografts arising
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not passaged in vitro, CSC biology depends on the latter form of
xenografts. Although the relevance of these, and all, xenografts to
patienttumorshasbeenquestioned [5–7],transplantationofhuman
cells into mice is the only model system that does not expose human
cells to an aphysiological ex vivo environment comprised of tissue
culture plastic and culture medium and which can recapitulate the
cellular heterogeneity of a primary tumor in vivo. Another topic of
controversy at the foundation of the CSC hypothesis is the
proposition that complete heterogeneity of a tumor can result from
a single cell [8,9]. Disregarding the stromal, endothelial, and
hematopoietic elements recruited and incorporated into the tumor,
it has been suggested that TG and NTG populations arise from
different cells and not from a single CSC [9]. If CSC can indeed
generate the cellular heterogeneity observed in patient tumors, and
mouse xenografts composed of cells strictly passaged in vivo best
maintain characteristics of tumors in patients, then the focus of
efforts in the cancer biology field should be squarely on these cells
and their microenvironmental niche.
Chemotherapeutic strategies that target rapidly dividing cells
have principally been used to treat tumors of epithelial origin.
While often effective at debulking tumor mass, these agents have
largely failed to eradicate disease [10]. A reason often attributed to
this failure is that subsets of cells gain resistance to therapy through
genetic mutation and natural selection. While this conjecture may
hold true, particularly in a setting of prolonged treatment, one
tenet of the ‘‘cancer stem cell hypothesis’’ posits that the cells
responsible for tumor recurrence may inherently be more resistant
to tumor debulking agents through any one of a number of
mechanisms; thereby explaining refractory tumor growth follow-
ing these treatments [11]. In support of this hypothesis, resistance
to radiation can result from elevated expression of DNA damage
response genes, as is the case for CD133
+ glioblastoma stem cells
[12]. In analogy to hematopoietic stem cells, solid tumor CSC
have been proposed to exhibit high level expression of multidrug
transporter family genes, such as ABCG2 and ABCB5, likely
resulting in more efficient efflux of chemotherapeutic drugs [13–
15]. CSC may also enter the cell cycle less frequently, allowing
them to resist toxicity by drugs that target highly proliferative cells.
Evidence for chemoresistance by stem-like cells in epithelial cell
lines and xenogeneic tumor-derived cells has been presented [16–
19]; however, these studies have either utilized cell lines adapted to
tissue culture and/or do not assess altered tumor-initiating cell
frequency in vivo following chemotherapy. By definition, tumor-
initiating cells are enumerated retrospectively, therefore altered
CSC frequencies post-therapy are best demonstrated by serial
transplantation.
Cyclophosphamide (CPA) and Irinotecan are agents that target
proliferating cells and are commonly used chemotherapeutic
agents in the treatment of solid tumors. Through different
mechanisms, both act to inhibit DNA replication resulting in the
slowing or inhibition of cell division and resulting in apoptosis.
Resistance to CPA has been suggested to result from high
cytoplasmic aldehyde dehydrogenase (ALDH) enzyme activity:
particularly that of ALDH1 and ALDH3 [20,21], which oxidize
and inactivate the bioactive metabolic byproduct of CPA,
aldophosphamide/4-hydroxycyclophosphamide (4-HC) [22,23].
ALDH1, in particular, may play a major role in CPA resistance,
as it’s Km for CPA is ,52 mM, whereas that of other ALDH family
members with CPA catabolic activity, ALDH3 (ALDH3A1) and
SSDH (ALDH5A1), are 10-fold lower (Km.520 mM) [24]. Though
many tissues are relatively resilient in the wake of CPA treatment
[25], only hematopoietic and neural stem cells have been
demonstrated to contain high ALDH activity in reconstituting
transplantation studies following isolation of these cell populations
[26–28]. Because colorectal cancer likely arises from colon stem or
progenitor cells, it is tempting to hypothesize that similar
mechanisms may render CoCSC resistant to CPA.
Cancer stem cell populations have now been prospectively
identified from various tumors of epithelial origin, including the
breast, colon and prostate [19,29–33]. In all colorectal tumors we
have investigated to date, tumors can be successfully transplanted
using small numbers (e.g. ,1,000) of cells phenotypically positive
for both epithelial-specific antigen (i.e. ESA or EpCAM) and CD44
[30]. In some tumors, isolation of cells positive for CD166, in
addition to ESA and CD44, further enriches for colorectal cancer
stem cells (CoCSC), allowing for efficient tumorigenesis with as
few as 200 ESA
+CD44
+CD166
+ cells [30]. Not only does this
phenotype identify CoCSC in xenograft tumors, but tumorigenesis
can be initiated from primary tumor samples with a small number
of ESA
+CD44
+CD166
+ cells. The reproducible identification of
CoCSC using ESA and CD44 facilitates not only therapeutic
efficacy studies across all patient-derived xenografts studied to
date, but also facilitates dissection of the molecular pathways
involved in tumorigenesis and resistance to therapy.
Here we demonstrate that human ESA
+CD44
+ CoCSC
generate adenocarcinomas that resemble parental tumors in both
their phenotype and histology upon serial transplant in a xenograft
setting and are enriched in tumors following classical chemother-
apeutic regimens intended to shrink tumors. We further
demonstrate both in vitro and in vivo that resistance to CPA is
mediated, at least in part, by ALDH1 enzyme activity and that
resistance to other chemotherapeutic agents (e.g. Irinotecan) is not
likely attributed to this mechanism. To the best of our knowledge,
this is the first functional demonstration that a human epithelial
CSC population, as defined by serial transplantation, is enriched
in residual solid tumors following chemotherapy. We further
demonstrate that tumor heterogeneity in the form of a complex
adenocarcinoma composed of TG and NTG populations can be
generated by a single cell. Finally, the experimental methods used
here provide a platform for assessing the efficacy of novel agents
targeting solid tumor stem cells.
Results
CoCSC are enriched in residual tumors following CPA
administration
Early passage human xenograft tumors generated from cells
never expanded in vitro appear to closely resemble those in patients
and thus may serve as an excellent model by which to study cancer.
We recently demonstrated that the subpopulation of human
colorectal tumor cells with an ESA
+CD44
+ phenotype is uniquely
responsible for generating heterogeneous adenocarcinomas in a
xenograft setting (Figure 1A & B)[30]. Human ESA
+CD44
+ cells
from xenogeneic colorectal tumors can be further subdivided based
on CD166 expression, resulting in enrichment for tumorigenic (TG)
cells among the CD166
+ population. In contrast, all remaining
cancer cells of human origin appear unable to initiate tumor growth
and are referred to as non-tumorigenic (NTG). Having identified
colorectal cancer stem cells (CoCSC) capable of fueling xenogeneic
tumor growth, we sought to address a lingering question in the field
regarding whether CSC are preferentially resistant to chemother-
apeutic drugs.
Cyclophosphamide (CPA) is an alkylating agent whose meta-
bolic byproduct, phosphoramide mustard, crosslinks DNA and
induces apoptosis in rapidly dividing cells [22]. CPA is a
commonly used chemotherapeutic drug in the treatment of
various types of cancer, such as soft tissue sarcomas, breast cancer
CoCSC Resist Chemotherapy
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colorectal cancer due to a prevailing resistance on the part of these
tumors. To investigate this resistance to therapy, we explored
whether CoCSC are enriched in residual tumors following CPA
administration in vivo. To address this subject of interest, tumors
were initiated with highly purified CoCSC from multiple
xenogeneic tumor lines (UM-C4 & UM-C6) and upon reaching
,400 mm
3, mice were randomized to receive either vehicle or
Figure 1. CoCSC phenotype cells preferentially survive CPA chemotherapy. A) Phenotypic profile of UM-C4 colorectal tumors for ESA, CD44
and CD166, following exclusion of mLin
2 cells. B) Formalin fixed, paraffin embedded tumor sections from CPA- or vehicle-treated control mice
stained with Hematoxylin & Eosin (H&E), for proliferating Ki-67
+, or for TUNEL
+ dead cells. Black bar=100 mm. C) Following randomization to
normalize treatment groups at 400 mm
3 at day 0, twice weekly administration of vehicle (green boxes) or 38 mg/kg CPA (red circles) commenced
and tumors were measured periodically. D) Phenotypic analysis of individual tumors, displaying the percentage of human tumor cells with the
ESA
+CD44
+ phenotype as a function of tumor size. E) Representative overlay histogram displaying CD166 surface expression on human ESA
+CD44
+
tumor cells from vehicle- or CPA-treated animals. The black line represents isotype control staining of ESA
+CD44
+ tumor cells.
doi:10.1371/journal.pone.0002428.g001
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and administration, tumor growth was noticeably retarded in the
CPA-treated animals (Figures 1C and Figure S1A). Following
euthanization, tumors were removed for histological and pheno-
typic analysis. Although the percentage of proliferating tumor cells
(i.e. Ki-67
+) did not appear altered, there was noticeably more cell
death (i.e. TUNEL
+ cells; Figure 1B) and ESA
+CD44
+ cells were
more frequent in tumors from CPA-treated mice (Figure 1D). The
trend towards more frequent ESA
+CD44
+ cells in CPA-treated
tumors generally held true independent of tumor volume and was
more pronounced at higher CPA doses (e.g. 38 mg/kg versus
25 mg/kg; data not shown). Enrichment of ESA
+CD44
+CD166
+
cells was even more striking and particularly evident when CD166
expression was analyzed on residual human ESA
+CD44
+ cells
(Figures 1E, S1B & C). Similar results were observed with both
xenogeneic tumor lines investigated.
To determine whether the phenotypic increase in CoCSC
following CPA administration correlated with an authentic rise in
TG cell frequency, we serially transplanted 4 sets of mice with bulk
UM-C4 tumor cells using a limiting dilution approach and scored
them as positive or negative for tumor growth after three months.
Mice with palpable tumors at 90 days were kept alive to determine
whether tumor growth would continue beyond 200 mm
3, as rare
palpable masses can occur, but which contain murine stromal
elements and no detectable human cells upon analysis at the
termination of the study (data not shown). Based on Poisson
distribution statistics, TG cells were .2.2-fold more frequent in
CPA-treated tumors than in mice administered vehicle
(P=0.0016; Table 1 & Figure 2A). Importantly, the cellular
phenotype of these serially transplanted secondary tumors were
identical to the parental tumor cells used to initiate the study
(Figure 2B), demonstrating that intervening treatment and serial
transplantation of cells in limiting dilution did not alter either the
tumorigenic potential of CoCSC nor their capacity to generate
heterogeneous tumors containing predominantly non-tumorigenic
(i.e. CD44
2) cells.
Because TG cells were more frequent and tumor cell
populations from CPA-treated animals were enriched for
phenotypes associated with CoCSC, we next isolated CoCSC
phenotype cells from UM-C4 tumors of vehicle- versus CPA-
treated mice and asked whether these cells inherently differed in
their ability to generate secondary tumors. Serial transplantation
of 50 ESA
+CD44
+ or ESA
+CD44
+CD166
+ cells from tumors in
CPA- versus vehicle-treated control mice resulted in secondary
tumors with roughly equal frequency (Table 1), which when
considered in conjunction with previous observations suggest that
CoCSC are more frequent within tumors exposed to CPA
chemotherapeutic regimens and are unaffected in their ability to
fuel tumor growth.
CoCSC have high expression of ALDH1A1
In searching for additional CoCSC markers, we previously used
a tool that can identify hematopoietic and neural stem cell
populations: ALDH enzyme activity [30]. Using the Aldefluor
TM
reagent, which undergoes a shift in fluorescence following
enzymatic cleavage by ALDH enzymes, and the ALDH1-specific
inhibitor diethylaminobenzaldehyde (DEAB) [34], a large sub-
population of ESA
+CD44
+ cells from both UM-C4 and UM-C6
tumor lines was determined to have high ALDH activity
(Figure 3A) [30]. Similar observations were also made in other
patient-derived xenograft colorectal tumor lines (Figure S2).
Furthermore, when ESA
+CD44
+ cells were subdivided based on
ALDH activity and isolated by FACS, ALDH
+ cells were
tumorigenic in all cases investigated [30]. Of note, tumorigenicity
is strictly conferred by ESA
+CD44
+ALDH
+ cells in the UM-C4
Figure 2. Tumorigenic UM-C4 cells are enriched in residual
tumors following CPA administration. A) Limiting dilution analysis
of unfractionated UM-C4 tumor cells was used to calculate TG cell
frequency using Poisson distribution statistics (695% confidence level;
*P =0.0016). B) Percentage of human ESA
+CD44
+ and
ESA
+CD44
+CD166
+ cells in secondary tumors arising from residual
tumorigenic cells transplanted serially in limiting dilution following
vehicle or CPA treatment regimens.
doi:10.1371/journal.pone.0002428.g002
Table 1.
Tumors/animals injected (%)
Cell type injected # cells Control CPA
Bulk Tumor Cells 1500 18/18 (100%) 18/18 (100%)
500 16/17 (94%) 19/19 (100%)
167 11/18 (61%) 13/18 (72%)
56 2/20 (10%) 12/20 (60%)
mLin
2ESA
+CD44
+ 50 3/6 (50%) 2/6 (33%)
mLin
2ESA
+CD44
+CD166
+ 50 7/10 (70%) 8/10 (80%)
doi:10.1371/journal.pone.0002428.t001
CoCSC Resist Chemotherapy
PLoS ONE | www.plosone.org 4 June 2008 | Volume 3 | Issue 6 | e2428colorectal tumor line (Figure 3B). Although tumors can arise from
ESA
+CD44
+ALDH
2 cells taken from the UM-C6, OMP-C5 and
OMP-C8 tumor lines [30], an ALDH
+ subset of TG ESA
+CD44
+
cells does exist in all xenogeneic colorectal tumor lines investigated
to date (n=6). In contrast, a subpopulation of CD44
2 cells with
high ALDH activity also exists in all tumor lines, but these cells fail
to generate tumors upon transplantation.
A subset of ALDH enzymes can oxidize, and thus inactivate, the
cytotoxic CPA metabolite 4-HC/aldophosphamide [23,35]. The
presence of cytoplasmic ALDH1 and ALDH3, in particular, have
been associated with CPA resistance in the A549 lung cancer cell
line [20,21]. ALDH1 (encoded by ALDH1A1) is greater than 10-
fold more efficient at catabolizing 4-HC/aldophosphamide than
its related family members ALDH3 and SSDH: encoded by the
ALDH3A1 and ALDH5A1 genes, respectively [24]. In Taqman
TM
qRT-PCR analysis of UM-C4 and UM-C6 tumors, ALDH1A1 is
generally expressed at higher levels than ALDH3A1 and
ALDH5A1. ALDH1A1 gene expression is 2.8-fold higher in CoCSC
than in NTG cells, and despite slight elevation of ALDH3A1
expression in CoCSC versus NTG populations (Figure 3C), its
message is barely detectible in either tumor line. Additionally,
whereas ALDH5A1 is slightly elevated in TG versus NTG cells
from UM-C4 tumors (,1.5-fold), its expression is similar among
these populations from UM-C6 tumors (Figure 3C). The
preferential expression of ALDH1A1 in TG cells supports observed
enzymatic activity measurements among the human ESA
+CD44
+
subpopulation, wherein the majority of these cells have high
DEAB-sensitive, ALDH1 activity. When considered in conjunc-
tion with the 10-fold higher proficiency of ALDH1 versus ALDH3
and SSDH at inactivating CPA intermediates [24], one might
interpret these results to suggest that CoCSC resistance to CPA
might be predominantly mediated by ALDH1 enzymatic activity.
ALDH1A1, MYC, and MYB are enriched in residual TG cells
post CPA therapy
Since ALDH1A1 gene expression is elevated in TG versus NTG
cells, ALDH1 enzymatic activity is disproportionably high in cells
with the CoCSC phenotype, and this activity may mediate
resistance to CPA, we next asked whether the frequency of
ESA
+CD44
+ALDH
+ cells was elevated in UM-C4, UM-C6 and
OMP-C8 tumors from mice receiving CPA versus those being
administered vehicle. Like the observed phenotypic increase in
CD166
+ cells (Figures 1E, S1B & S1C), the ALDH
+ subpopulation
of ESA
+CD44
+ cells was consistently higher in CPA- versus
vehicle-treated control mice (67.666.3% versus 56.866.8%,
respectively; n=5, P,0.012 in paired t-test) (Figure 4A).
A number of gene products have been deemed critical to
normal colon development and are widely expressed in colorectal
tumors [36–39]. Following the isolation of TG versus NTG
populations from both vehicle- and CPA-treated UM-C4 tumors
with .99% purity, expression of numerous genes with suggested
ties to colorectal cancer was determined by Taqman
TM qRT-
PCR. Those differentially expressed in TG versus NTG cells
included not only ALDH1A1, as described above (Figure 3C), but
also c-Myb (MYB) and c-Myc (MYC; Figure 4B). In contrast, genes
associated with differentiation and a mesenchymal phenotype
[40,41], such as Vimentin (VIM), were more highly expressed in
NTG cells.
Figure 3. ALDH1 enzyme activity demarcates a subpopulation
of CoCSC. A) Phenotypic profile of human ESA
+ UM-C4 tumor cells for
ALDH1 enzymatic activity. Gates demarcate tumor subpopulations
isolated by FACS for tumorigenicity studies, wherein B) growth kinetics
of CD44
+ALDH
+ (red circles), CD44
+ALDH
2 (orange boxes) and
CD44
2ALDH
+ (green triangles) populations are plotted. Measurements
reflect only mice with palpable tumors. Data representative of n=3
independent experiments. C) Taqman qRT-PCR data displaying relative
expression of ALDH1A1 (1A1), ALDH3A1 (3A1) and ALDH5A1 (5A1)i n
tumorigenic (TG; black) versus non-tumorigenic (NTG; white) cells (n$2)
from 2 patient-derived xenogeneic colorectal tumor lines (UM-C4 & UM-
C6). Data reflects Mean6SEM, is normalized versus GUSB and displayed
relative to UM-C4 NTG expression for each gene.
doi:10.1371/journal.pone.0002428.g003
CoCSC Resist Chemotherapy
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expressing high levels of tumorigenicity-associated markers, such
as CD166, relative expression of CoCSC-associated versus NTG-
associated transcripts, such as ALDH1A1 and VIM, respectively,
was further disparate in CPA- versus vehicle-treated control UM-
C4 tumors (Figure 4B). Consistent with the hypothesis that
ALDH1 may have a role in mediating resistance to CPA,
ALDH1A1 gene expression was further elevated in residual cells
with the CoCSC phenotype, but ALDH3A1 and ALDH5A1 were
not (Figures 4B & S3). In addition, genes previously identified as
highly expressed in the epithelial stem/progenitor cell compart-
ment at the base of colon crypts and in neoplastic tissue (e.g. MYB
& MYC) were more highly expressed in residual tumor CoCSC
than the NTG population of cells that represent the bulk of the
tumor, but which are generated by CoCSC and appear more
susceptible to CPA-induced cytotoxicity. Similar expression
patterns were also observed in other xenogeneic tumor lines
following CPA-treatment, including UM-C6 (Figure S3).
Finally, gene expression differences in CPA- versus vehicle-
treated control tumors were further correlated with protein
expression by immunofluorescence and IHC. Intracellular levels
of ALDH1 and nuclear c-Myc, for example, were more prevalent
in CPA-treated tumors (Figure 4C). Interestingly, ALDH1 staining
in CPA-treated tumors appeared to localize to the apical surface,
where it may be hypothesized to intercept CPA metabolites as they
enter the cell. In contrast, ALDH1 protein levels were lower and
more diffuse in control tumors. Similarly, c-Myc was noticeably
more concentrated in the nucleus of colorectal tumor cells of CPA-
treated mice, consistent with the increased frequency of TG cells
and elevated MYC expression within this resilient population.
CoCSC resistance to chemotherapy is not specific to CPA
To determine whether CoCSC also exhibit resistance to other
important chemotherapeutic agents, we examined the impact of
Irinotecan (a.k.a. SN-38) on CoCSC frequency. Experiments were
initiated whereupon tumor bearing mice received weekly injections
of 15 mg/kg Irinotecan. After a slight delay of approximately
1 week, tumor growth was halted by Irinotecan (Figure 5A). Upon
tumor harvest two weeks after the initiation of chemotherapy, the
percentage of remaining CoCSC was assessed by flow cytometry. In
Irinotecan-treated tumors, the percentage of bulk tumor cells with
the CoCSC phenotype was increased 61% versus control mice
administered vehicle (Figure 5B). Next, the inherent tumorigenicity
of ESA
+CD44
+CD166
+ cells from vehicle- or Irinotecan-treated
mice was tested in a serial transplant setting versus those cells that
did not phenotypically classify as CoCSC. Similar take rates were
observed with CoCSC from control- or Irinotecan-treated tumors
in these transplants, and cells phenotypically classified as ‘‘Other’’
did not initiate tumors (data not shown). The increased frequency of
CoCSC phenotype cells in residual tumors from mice administered
Irinotecan and the inability of cells with other phenotypes to
transplant disease, together suggest that CoCSC are also preferen-
tially resistant to Irinotecan.
CPA resistance is specific to cells with high ALDH1
activity
Seeing that ESA
+CD44
+ tumor cells have high ALDH activity,
the frequency of ESA
+CD44
+ALDH
+ cells is increased in tumors
from mice treated with CPA, and ALDH1A1 gene expression is
elevated in CPA-resistant CoCSC, we therefore sought to
determine whether resistance to CPA was mediated by ALDH1
enzyme activity. Because the ALDH1 specific inhibitor DEAB is
highly unstable in vivo [42], in vitro culture conditions that support
TG colorectal tumor cell expansion were established. Notably, the
cellular phenotype of cells best able to establish colonies in vitro was
ESA
+CD44
+CD166
+ (also that of CoCSC), whereas FACS
purified CD44
2 cells were unable to do so (data now shown).
To validate that this culture system supports maintenance of TG
cells, we sorted ESA
+CD44
+CD166
+ CoCSC in limiting dilution
into plates containing Mitomycin C-treated 3T3 or MEF feeder
cells as support, depending on the tumor line used: UM-C4 or
UM-C6, respectively. Colony formation frequency of CoCSC
under these conditions was roughly similar to the TG cell
frequency observed upon transplantation (,1:86633; n=7 for
UM-C4 and 1:5265; n=3 for UM-C6). Colonies were cultured
for 14 days without passaging prior to reimplantation into mice.
Not only did cells maintain ESA, CD44 and CD166 expression
during in vitro culture (Figures 6A & B), but the ability to generate
heterogeneous tumors resembling parental tumors was conserved
as well (Figure 6C). To validate that tumor-initiating cells in
Figure 4. CoCSC with high ALDH1 activity are more prevalent
following CPA therapy. A) Ratio of ALDH
+ tumor cells among the
human ESA
+CD44
+ population in tumors from vehicle-treated control or
CPA-treated mice. Data reflects the paired Mean of 5 independent
experiments using 3 different xenogeneic colorectal tumor lines (UM-
C4, UM-C6 & OMP-C8) and n$5 mice per experiment. B) Taqman qRT-
PCR data for the denoted genes using TG and NTG populations isolated
from (V) vehicle- or CPA-treated UM-C4 tumors. Data represents
Mean6SEM (n$2). C) Immunofluorescence or immunoperoxidase
staining of frozen or formalin-fixed, paraffin embedded tumors for
ALDH1 or c-Myc, respectively, from vehicle- and CPA-treated mice. Black
bar=100 mm.
doi:10.1371/journal.pone.0002428.g004
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parental tumors and were derived from a single cell, UM-C4 cells
were transduced with a lentivirus carrying GFP-Luciferase, tumors
were generated, and single colonies obtained from
ESA
+CD44
+CD166
+ cells were transplanted into mice. Upon
harvest of these tumors derived from a single colony, either cells
with the CoCSC phenotype or all other tumor cells with differing
phenotypes were isolated by FACS, and tumorigenicity and
clonality studies were performed. An input of 2,000 FACS purified
cells resulted in a 100% take frequency with CoCSC phenotype
cells, whereas human cells with all other phenotypes generated
only 1 tumor (of 10 mice transplanted); likely resulting from rare
contaminating CoCSC (Figure 6D). Of note, tumor heterogeneity
can result from a single cell, as lentiviral transduction studies show
that both ESA
+CD44
2 (i.e. NTG) and ESA
+CD44
+CD166
+ (i.e.
CoCSC) cells have identical lentiviral insertion sites (Figure 6D
inset), but only CoCSC are able to propagate tumors. Phenotypic
and histological analysis of these serially transplanted tumors,
which originated from single in vitro colonies, show that the ability
to generate adenocarcinomas similar to parental UM-C4 tumors is
maintained during short-term in vitro culture in these conditions
(Figures 6E & F).
To test whether CPA resistance is mediated by ALDH1 enzyme
activity, UM-C4 or UM-C6 colorectal tumor cell colonies
established in vitro over the course of 3–4 days were then exposed
to the bioactive CPA-metabolite, 4-HC, for 4 hours without or
including various concentrations of the ALDH1-specific inhibitor,
DEAB. In the absence of DEAB, the EC50 of 4-HC was ,60 mg/
mL (Figure 7A). Inhibition of ALDH1 activity resulted in
increased susceptibility to 4-HC mediated cell death, as the
EC50 was shifted to 43 mg/mL and 6 mg/mL in the presence of
30 mM and 100 mM DEAB, respectively. Like DEAB, all-trans
retinoic acid (ATRA) has been demonstrated to reduce ALDH
enzyme activity; however, it does so by reducing ALDH1 and
ALDH3 protein levels [43]. Like DEAB, pre-treatment with 1 mM
ATRA sensitized colorectal tumor colonies to 4-HC (n=3;
P,0.015) (Figure 7B). Surprisingly, the combination of ATRA
pre-treatment and concurrent DEAB exposure synergized to
facilitate increased chemosensitivity (n=3; P=0.003). Preferential
ALDH1A1 gene expression in CoCSC and sensitization of
colorectal tumor cells to 4-HC by inhibiting ALDH1, together
strongly suggest that ALDH1 enzyme activity mediates CPA
resistance.
The above observation raised the question as to whether high
ALDH1 enzyme activity also confers resistance to Irinotecan. We
next established colonies of colorectal tumor cells and exposed
them to serial dilutions of Irinotecan for one week in the presence
or absence of 75 mM DEAB; a concentration known to potently
inhibit ALDH1 activity. In contrast to 4-HC, the unaltered
cytotoxicity profile of Irinotecan despite the presence of DEAB
(Figure 7C) suggests that inherent resistance of CoCSC to
Irinotecan occurs by a mechanism other than ALDH1 enzyme
activity. Of note, neither DEAB nor an equal volume of its vehicle
(1:200 dilution of 95% Ethanol) significantly reduced proliferation
or survival during extended culture (7 days), suggesting that
ALDH1 activity is only critical in a chemotherapeutic setting.
ALDH1 is a major mediator of CoCSC resistance to CPA
The above in vitro studies strongly suggest that the ALDH1A1
gene product, ALDH1, mediates resistance to CPA. To determine
the importance of ALDH1 to CoCSC tumorigenicity and
resistance to CPA, we transduced UM-C6 tumor cells with
shRNA targeting ALDH1A1. UM-C6 tumors were chosen because
of their high ALDH1A1 expression and relatively low expression of
other ALDH family members (e.g. ALDH3A1 & ALDH5A1; see
Figure 4C). Cells successfully transduced with either an ALDH1A1-
targeted shRNA or Luciferase-targeted shRNA control vector
were isolated by FACS and implanted subcutaneously to generate
tumors. Taqman
TM qRT-PCR studies of UM-C6 tumor cells
verified that ALDH1A1 gene expression was reduced 88% versus
Luciferase-targeted shRNA transduced control cells, whereas
neither ALDH3A1 nor ALDH5A1 gene expression were altered
(Figure 8A). After tumors reached roughly 175 mm
3, tumors were
randomized within each group and then either treated with vehicle
or 38 mg/kg of CPA, twice weekly. By ten days post-randomiza-
tion, tumors in vehicle-treated mice from both groups had almost
doubled in size. Of note, the growth of ALDH1A1-targeted shRNA
transduced cells did not differ significantly from controls (not
shown). Consistent with observations described above, control
Luciferase-targeted shRNA transduced tumors undergoing a
regimen of CPA were retarded in their growth versus vehicle-
treated controls (Figure 8B; open circles). In agreement with results
observed in vitro with the ALDH1 inhibitor, DEAB, shRNA
targeting of ALDH1A1 gene expression appeared to sensitize
tumors to CPA in vivo, as tumor growth essentially stopped,
whereas ALDH1A1-targeted shRNA cells treated with vehicle
continued to grow (Figure 8B; black triangles). Compared to
vehicle-treated, ALDH1A1-targeted shRNA containing tumors, the
Figure 5. CoCSC phenotype cells are also enriched following
Irinotecan treatment. A) Upon randomization to normalize treatment
groups at 400 mm
3 at day 43, once weekly administration of vehicle
(green boxes) or 15 mg/kg Irinotecan (red triangles) commenced and
tumors were measured twice weekly. Growth curves representing the
Mean6SEM are shown. B) Percentage of human ESA
+CD44
+CD166
+
CoCSC phenotype cells in residual tumors is shown. Data reflects n$4
mice per treatment group.
doi:10.1371/journal.pone.0002428.g005
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groups significantly differed by day 10 (n$5, P=0.0061).
Upon termination of the study, tumors were removed and the
cellular phenotype was assessed to determine whether CoCSC
frequency differed in tumors where ALDH1A1 gene expression was
being suppressed by shRNA. Whereas control Luciferase-targeted
shRNA tumors were significantly enriched for
ESA
+CD44
+CD166
+ cells in CPA- versus vehicle-treated mice
(n$5, *P=0.0002), both CoCSC and NTG cells from ALDH1A1-
targeted shRNA containing tumor cells appeared equally sensitive
to CPA, as the frequency of CoCSC was no different (Figure 8C).
Of note, shRNA-mediated knockdown of ALDH1A1 in vivo,
significantly reduced the frequency of CoCSC in residual tumors
following CPA therapy (n$6, **P=0.045).
Discussion
While recent decades have witnessed a revolution in therapeutic
strategies yielding significant clinical responses measured in terms
of tumor regression and disease-free survival, overall survival has
failed to substantially improve. The recent identification of tumor
cell subpopulations with the unique ability to fuel tumor growth
(i.e. CSC) may shed light on the disconnect between response rates
and overall survival. That is, therapies that fail to adequately target
CSC populations, which represent a minority of most epithelial
tumors, will fail to eliminate those cells capable of regenerating the
tumor after therapy has ceased. Furthermore, survival of these
long-lived cells in the presence of toxic therapeutic agents provides
an ideal selective vice for additional mutations. Familiarity with
both the means of resistance to a particular chemotherapeutic
agent and the phenotypic identity of those cells that harbor
resistance mechanisms should help facilitate the discovery of
therapies better able to clear minimum residual disease and
prolong overall survival. Although the cancer stem cell paradigm
explains tumor heterogeneity, provides rationale for how genetic
mutations might be accumulated over long time periods and
suggests resistance to chemotherapeutics/radiation may be
inherent and not acquired properties of specific tumor cell
subpopulations in epithelial tumors [1,2], a few key tenets of this
theory have not been supported experimentally. Having previously
identified surface markers that reliably identify colorectal cancer
stem cells (CoCSC)[30], we show here that colorectal tumors are
enriched for CSC following chemotherapeutic regimens that halt,
or at least slow, tumor growth. ALDH1 enzymatic activity, which
is generally highest in CoCSC, appears to play a major role in
mediating resistance to CPA, as its inhibition in vitro, and reduced
expression in vivo, sensitizes colorectal tumor cells to the bioactive
metabolite of CPA. This chemotherapeutic resistance mechanism
does not appear universal; however, as altered cytotoxicity profiles
were not observed with other chemotherapeutic agents (e.g.
Irinotecan) en lieu of ALDH1 inhibition.
ESA and CD44 demarcate the subpopulation of cells with
tumorigenic ability in all colorectal tumors examined to date.
Overexpressed in a number of epithelial tumors and suggested to
be an important prognostic marker of tumor progression [44],
CD166 (i.e. ALCAM) appears to further segregate TG from NTG
Figure 6. In vitro maintenance and expansion of CoCSC. Human ESA
+CD44
+CD166
+ cells were plated in limiting dilution and cultured for
fourteen days in serum-free maintenance conditions. Colorectal tumor colonies were then either analyzed for A) ESA expression by IHC, or B) ESA,
CD44 and CD166 expression by flow cytometry. C) Cellular phenotype of single colony-derived tumors, showing human ESA
+ cell subpopulations
expressing CD44 and CD166. D) Tumor growth curves are shown for either 2,000 CoCSC phenotype cells or an equal number of cells with all other
phenotypes (Other), which were isolated from in vitro colony-derived tumors (tumors/animals injected). Inset shows lentiviral insertion band obtained
by inverse PCR of 1) human xenograft tumor cells, 2) ESA
+CD44
+CD166
+ (CoCSC) cells or 3) ESA
+CD44
2 (Other) cells isolated by FACS. Phenotypic and
morphological analysis of single-cell derived tumors from serially transplanted CoCSC show that the diverse E) phenotype and F) histological makeup
of xenogeneic colorectal tumors are maintained following brief in vitro culture in limiting dilution. Black bar=100 mm.
doi:10.1371/journal.pone.0002428.g006
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Consistent with the hypothesis that TG cells are more resistant to
chemotherapy and the association between CD166 expression and
poor outcome, the tumorigenic CD166
+ subset of ESA
+CD44
+
cells appeared more resilient to not only CPA, but also Irinotecan.
Like the normal colon crypt, which is predominantly composed
of two different cell lineages (i.e. absorptive colonocytes and goblet
Figure 7. ALDH1 enzyme inhibition sensitizes colorectal tumor
cells to CPA in vitro. In vitro cell viability measurements of human
colorectal tumor cells following 4 hours of exposure to A) varying
concentrations of 4-HC and/or the ALDH1-specific inhibitor DEAB, or B)
20 mg/mL 4-HC in the presence or absence of 75 mM DEAB and/or 1 mM
ATRA. C) Cell viability measurements following 7 days of exposure to
varying concentrations of Irinotecan in the presence or absence of
75 mM DEAB. All data is expressed as the Mean6SEM of triplicate
measurements and is normalized versus vehicle-treated controls. All
data is representative of n$2 independent experiments using either
UM-C4 or UM-C6 tumor cells. *P,0.015. **P=0.003.
doi:10.1371/journal.pone.0002428.g007
Figure 8. Knockdown of ALDH1A1 gene expression sensitizes
tumors to CPA in vivo. UM-C6 tumor cells transduced with
Luciferase- (black) or ALDH1A1-targeted shRNA (white) were A) assessed
by Taqman
TM qRT-PCR for relative expression of ALDH1A1, ALDH3A1
and ALDH5A1,o rB) transplanted into mice at 400 cells/mouse to initiate
tumors. Following randomization when tumors reached a Mean volume
of 175 mm
3, mice were treated twice weekly with either vehicle or
38 mg/kg CPA. The Mean difference in tumor volume between CPA-
and vehicle-treated mice is plotted for Luciferase shRNA control (open
circles) or ALDH1A1 shRNA-containing (triangles) cells. C) Percentage of
human ESA
+CD44
+CD166
+ CoCSC phenotype cells in residual tumors is
shown. Data reflects n$5 mice per treatment group.
doi:10.1371/journal.pone.0002428.g008
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immature and mature colorectal cell lineages that are somewhat
unstructured in their organization. Proto-oncogenes such as c-
Myb not only coordinate normal development of the distal colon,
but altered expression is commonly associated with hyperproli-
feration of immature colorectal cells and overt cancer [37,45]. c-
Myc has recently been demonstrated to mediate nuclear b-
catenin-mediated tumorigenesis in the APC-deficient mouse
model of intestinal neoplasia [46]. In fact, MYB appears to be a
downstream target of c-Myc. Of significant interest in studies
performed here is the observation that MYC expression is elevated
in TG versus NTG cells from xenogeneic colorectal tumors, and
that MYC levels are further increased in residual cells with the
CoCSC phenotype. Conversely, MYC levels do not change, or are
reduced in the NTG contingent of tumor cells, which themselves
are progeny of CoCSC. These observations corroborate past
studies demonstrating the association of the MYB and MYC proto-
oncogenes with cancer, but underscore the distinction between
TG versus NTG cells, in that those cells most resistant to therapy
(i.e. CoCSC) also most resemble stem/progenitor cells in their
phenotype and gene expression profiles.
Establishing mechanisms of resistance to chemotherapeutic
drugs can be difficult, especially with heterogeneous xenogeneic
tumors. However, in vitro culture conditions that facilitate colony
formation with an input of tumorigenic colorectal tumor cells have
been established and offer a new approach to the characterization
of underlying mechanisms of drug resistance. Culture of CoCSC
in these conditions is herein demonstrated to generate morpho-
logically and histologically diverse tumors from limiting dilutions
of colorectal tumor cells. That is, minimally cultured individual
colonies generated in vitro are able to generate tumors in vivo that
resemble the parental adenocarcinomas from which they were
obtained. We further show for the first time that tumor
heterogeneity can result from a single CoCSC using classical
lentiviral insertion site analysis. Because in vitro colonies are highly
enriched for TG ESA
+CD44
+CD166
+ cells, the fate of these cells
in defined culture conditions can now be assessed without the
dangers encompassing extended in vitro culture and passaging.
Intracellular ALDH enzymes oxidize aldehydes to carboxylic
acids and carry out various catabolic processes, including ethanol
and amine catabolism and conversion of vitamin A to retinoic acid
[23]. ALDH enzyme activity can also protect cells from the
cytotoxic affects of CPA, as a subset of ALDH enzyme family
members can catabolize the bioactive metabolite of CPA,
aldophosphamide/4-HC [22]. Although ALDH1A1, ALDH3A1,
and ALDH5A1 gene products can degrade biologically active CPA
metabolites [20,21], DEAB appears to specifically inhibit ALDH1
[34]. Like hematopoiesis, intestinal epithelium is resilient following
damage incurred during CPA therapy [25]. Hematopoietic stem
cells (HSC) have high ALDH1 activity and can be isolated from
bone marrow based on that unique trait [27,28]. Similarly, we
suggest that stem/progenitor cells in the base of colon crypts, like
CoCSC, may have high ALDH1 activity, thus providing
protection against CPA-induced cytotoxicity and tissue ablation
during therapy. As in vitro experiments suggest, inhibition of
ALDH activity in vivo sensitizes tumors to CPA therapy; however,
the half-life of DEAB in vivo is extremely short [42] and such
studies cannot be done. Knock down of ALDH1A1 expression
using a lentiviral-based shRNA approach in UM-C6 tumors
demonstrated that CoCSC can be sensitized to CPA in vivo,a s
there was no noticeable enrichment of CoCSC in tumors from
CPA- versus vehicle-treated mice. Furthermore, unlike for 4-HC in
vitro, DEAB was unable to alter colorectal tumor cell sensitivity to
Irinotecan, suggesting that the target of this inhibitor (ALDH1
enzyme activity) plays an important role in resistance to CPA, and
resistance to Irinotecan appears to involve another mechanism.
Like DEAB, retinoic acid (a vitamin A/retinaldehyde metab-
olite and product of ALDH activity) appears to decrease ALDH1
and ALDH3 protein levels via a feedback mechanism that can
sensitize cells to CPA-induced cytotoxicity [23,43]. Retinoic acid,
in the form of ATRA, is used with great success in the clinical
setting for a subset of acute promyelocytic leukemia patients who
have chromosomal translocations involving the retinoic acid
receptor-a gene, RARa [47], but the use of retinoids in solid
tumors has not been promising to date [48]. As we demonstrated
here, either DEAB or ATRA alone sensitize colorectal tumor cells
to 4-HC, and the combination of both appears synergistic.
Because normal stem cell populations, such as HSC, neural stem
cells and in all likelihood, intestinal stem cells, have high ALDH
activity, its inhibition by ATRA as a pre-therapeutic regimen to
CPA may also negatively impact normal stem cell populations.
Nevertheless, as shown here, detailed study of rare tumor
populations responsible for fueling tumor growth can provide
mechanistic insights not only into tumorigenesis, but resistance
mechanisms to common therapies. These inherent resistance
mechanisms can include drug specific catabolic enzyme activity;
such as that of ALDH1.
Here we show that xenogeneic colorectal tumors investigated to
date contain a subset of TG ESA
+CD44
+ cells with high ALDH
activity, and that this subpopulation is enriched in xenogeneic
tumors from mice treated with CPA. These observations are
supported by qRT-PCR using TG or NTG cells isolated by
FACS, which show that ALDH1A1 is the predominant cytoplasmic
ALDH enzyme in colorectal tumors and its expression is further
increased in residual tumor cells following therapy with CPA;
consistent with the phenotypic increase in ALDH
+ cells among the
CoCSC phenotype. Importantly, however, ALDH1 activity alone
does not confer tumorigenicity nor demarcate TG cells. When
tumorigenicity of CD44
+ versus CD44
2 ESA
+ALDH
+ cells is
compared, only the CD44
+ subset is able to initiate actively
growing tumors. Secondly, extended inhibition of ALDH1 activity
with DEAB in vitro does not appear to alter cell proliferation or
survival, as its presence in Irinotecan combination studies for
7 days in vitro did not differ from control. Furthermore, initiation
of tumorigenesis with ALDH1A1- versus Luciferase-targeted
shRNA containing cells was identical, demonstrating that ALDH1
enzymatic activity is not requisite in the absence of CPA exposure.
The advent of flow cytometry and cell sorting has revolutionized
the study of developmental biology and disease, particularly in the
hematopoietic system. Hematologic malignancies are among the
best understood of the neoplastic diseases precisely because
hematopoietic cells are easy to obtain and the in vivo and in vitro
assays to determine the fate and potential of these cells have been
developed. Similarly, the field of solid tumor biology has begun to
enter an era where the cells responsible for fueling tumor growth
can be identified, isolated, and their characteristics tested both in
vivo and in vitro. Here we demonstrate for the first time that CoCSC
are responsible for fueling both tumor growth and heterogeneity,
and are enriched in residual tumors following chemotherapy. We
also reveal that inherent resistance mechanisms differentially
expressed within tumor subpopulations, such as ALDH1 enzy-
matic activity in CoCSC, can explain the inability of chemother-
apeutic agents to improve overall survival despite tumor
regression. In addition to providing evidence supported by serial
transplantation studies for a previously unsupported tenet of the
‘‘cancer stem cell hypothesis’’, we identify a major CSC-specific
mechanism of resistance to a classical chemotherapeutic agent and
establish experimental platforms both in vitro and in vivo for testing
CoCSC Resist Chemotherapy
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care therapies. Closer scrutiny of both normal tissue-resident stem
cells and CSC will lead to a better understanding of disease
mechanisms and, ultimately, better therapies.
Materials and Methods
Xenograft Line Propagation
Human colorectal tumor lines used in this study were obtained
and passaged in mice as previously described [30]. Briefly, all
tumors were initiated by subcutaneous implantation of either bulk
tumor cells from frozen stocks or FACS purified cell populations
into 6–8 week old NOD/SCID mice (Jackson Laboratories). Mice
were anesthetized with Isoflurane or a single IP injection of 75–
100 mg/kg Ketamine and 5–10 mg/kg Xylazine. Of the 3
xenograft lines used in this study, two (UM-C4 & UM-C6)
originated at the University of Michigan and one (OMP-C8)
originated at OncoMed Pharmaceuticals Inc. All experiments
were carried out under approved institutional IACUC guidelines
and protocols.
Tissue Disaggregation and Cell Preparation
Tumor tissue was minced into tiny fragments (,2m m
3),
followed by enzymatic digestion with 300 u/mL Collagenase,
100u/mL Hyaluronidase, 0.5 mg/mL Dispase and 100 u/mL
DNAseI (all obtained from Stem Cell Technologies; Vancouver,
BC) for 1 hour at 37uC/5% CO2 with intermittent pipetting to
disperse cells. Cells were then filtered sequentially through 70 mm
and 40 mm screens, followed by a wash with excess FACS Buffer
(16Hanks Buffered Saline Solution [HBSS], 2% Heat-inactivated
Fetal Calf Serum [FCS] and 25 mM HEPES [pH 7.4]). Red
blood cells were lysed during a brief exposure to Ammonium
Chloride and washed again with excess FACS buffer.
Flow Cytometry and Cell Sorting
All analyses and cell isolations were performed using freshly
dispersed cell suspensions. Antibody staining was performed in
FACS buffer for 30 minutes at 4uC at a density of 1610
7 cells/
mL. Antibodies used in this study include: anti-mouse H-2K
d
(SF1-1.1; BD Pharmingen), anti-mouse CD45 (30-F11; BioLe-
gend), anti-human ESA (HEA-125; Miltenyi Biotec), anti-mouse/
human CD44 (IM7; eBioscience), anti-human CD49f (GoH3; BD
Pharmingen) and anti-human CD166-PE (105902; R&D Systems).
The Aldefluor
TM reagent was purchased from StemCell Technol-
ogies and used per manufacturer instructions. In all experiments,
cells staining positively for murine lineage markers (mLin
+; H-2K
d
and murine CD45) were excluded during flow cytometry using
Cy5.5PE-labelled antibodies. Dead cells were excluded using the
viability dye DAPI and cell doublets and clumps were excluded
using doublet discrimination gating. Cellular phenotype and
viability of FACS purified cells was confirmed by serial flow
cytometric analysis prior to injection for tumorigenicity studies.
Purity was typically .99%.
Tumorigenicity Experiments
Following gentle centrifugation at 900 rpm65 min, cells were
resuspended in 50 mL of FACS buffer per mouse and mixed 1:1
with Matrigel (BD Biosciences), followed by subcutaneous
injection into the lower abdominal region while mice were under
general anesthesia as described above. Only one tumor was
initiated per mouse. Health was monitored daily and tumor
growth was measured weekly using a digital caliper for up to
4 months. Animals were euthanized when tumors exceeded
1500 mm
3 or the 120 day timepoint was reached. Statistical
analysis of tumor growth includes only those mice with palpable
tumors (Mean6SEM).
Chemotherapy Regimen
Female mice were implanted with mLin
2ESA
+CD44
+ cells (400
per mouse) while under anesthesia as described above. Once
palpable, tumors were calipered twice weekly, and their length and
width were used to calculate tumor volume based on the following
formula: V=(length6[width])
2/2. When tumors reached
,400 mm
3, mice were randomized into either the control group,
which received vehicle (sterile water), or the therapeutic group,
which received CPA administered intraperitoneally at the dose of
38 mg/Kg twice a week. Irinotecan was diluted in PBS and
similarly administered once weekly at a dose of 15 mg/kg.
Immunohistochemistry
Immunohistochemical studies were performed on formalin-
fixed paraffin embedded tissues using monoclonal antibodies
raised against Ki-67 (Vector Laboratories, catalog number VP-
RM04) and c-Myc (DAKO, Catalog number M3570). Briefly,
4 mm-thick paraffin sections were deparaffinized and hydrated.
Antigen retrieval was performed in 0.1M Tris-Cl, pH 9.0, using
the Decloaking chamber from Biocare. Sections were then
incubated with 3% hydrogen peroxide to block endogenous
peroxidase activity and incubated with 1:50 dilution of primary
antibody for 1 hr at room temperature, and then detected using
ImmPRESS anti-mouse or anti-rabbit Ig (peroxidase) followed by
VectorH NovaRED
TM substrate for visualization (Vector Labora-
tories). Hematoxylin was used for counter staining. TUNEL
staining was performed using the In Situ Cell Death Detection
TM
kit (Roche). For Immunofluorescence staining of ALDH1
(Abcam), frozen sections were fixed with 220uC cold methanol
for 10 min, followed by a blocking step. Sections were incubated
with ALDH1 at 1 ug/ml for 1 hr at room temperature and
visualized with anti-mouse antibody conjugated with Alexa Fluor
488. Anti-hapten IgG was used as negative control and mounted
with Prolong Gold DAPI containing antifade (Invitrogen).
In Vitro Culture & Cytotoxicity Studies
Following tissue disaggregation, as described above, cell
suspensions were depleted of murine lineage cells using magnetic
beads and plated in 96-well Primaria (BD Bioscience) plates at a
density of ,20,000 cells per well in serum free Medium-D (3:1 low
glucose DMEM:F-12 Media, B27 supplement, ITS-X, Pen/Strep
[all from Invitrogen] and 0.5 mg/mL hydrocortisone [Stem Cell
Technologies]), supplemented with 20 ng/mL bFGF and EGF, 5
u/mL Heparin and 1610
6 u/mL LIF. Plates were gently spun at
500 rpm for 5 min at room temperature following plating to
promote attachment. When cultured in vitro for more than 7 days,
media was changed weekly.
For cytotoxicity studies, cells were cultured for 3–4 days at
37uC/5% CO2/5% O2, non-attached cells were removed, and
medium was replaced with that containing 4-hydroxycyclopho-
sphamide (4-HC; obtained from Dr. OM Colvin; Duke University
Medical Center), diethylaminobenzaldehyde (DEAB; Sigma),
Irinotecan or their respective vehicle. In studies using 4-HC, cells
were exposed for only 4 hours, after which the medium was
removed, cells were washed twice with PBS, and fresh Medium-D
was added. In experiments involving ATRA, cells were pre-
incubated overnight prior to exposure to DEAB and/or 4-HC.
Cell viability was then assessed using CellTitre-Glo (Promega)
either 20 hr post-treatment for 4-HC studies, or 1 week after
addition of Irinotecan.
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To assess clonality using lentiviral insertion site analysis, or
introduce shRNA targeting ALDH1A1 or Luciferase, UM-C4 and
UM-C6 tumor cells were transduced in vitro over a 3–4 day period.
Lentiviral vectors used for these studies contained either an eGFP-
Luciferase fusion gene (pLOM65) for clonality studies, or
ALDH1A1 (pLOM205) or a control Luciferase (pLOM145)
targeted shRNA embedded in the eGFP mRNA; each of which
is driven by the CMV promoter. Cells were isolated by FACS
based on GFP fluorescence and transplanted into mice. For
clonality studies, pLOM65-transduced cells were deposited into
96-well plates in limiting dilution and single colonies were injected
into mice 14 days later. Lentiviral insertion site analysis was
performed as described elsewhere [49] using the NlaIII restriction
endonuclease.
Supporting Information
Figure S1 CoCSC phenotype cells preferentially survive CPA
chemotherapy. UM-C6 tumors were initiated with ESA
+CD44
+
cells isolated by FACS. A) After randomization to normalize
treatment groups at 400 mm
3 at day 0, twice weekly administra-
tion of vehicle versus 38 mg/kg CPA commenced and UM-C6
tumors were measured periodically. B) Representative phenotypic
analysis of vehicle-treated control and CPA-treated tumors for
human UM-C4 ESA
+CD44
+CD166
+ cells. Mean6SEM. C)
Representative overlay histogram displaying the CD166 expres-
sion on human UM-C6 ESA
+CD44
+ cells.
Found at: doi:10.1371/journal.pone.0002428.s001 (10.40 MB
TIF)
Figure S2 Xenogeneic colorectal tumor lines contain a subset of
ESA
+CD44
+ cells with high ALDH activity. Phenotypic profile of
human ESA
+ cells from various xenogeneic colorectal tumor lines
for CD44 and ALDH enzymatic activity in the presence or
absence of the ALDH1-specific inhibitor, DEAB.
Found at: doi:10.1371/journal.pone.0002428.s002 (10.14 MB
TIF)
Figure S3 UM-C6 CoCSC with high ALDH1 activity are more
frequent following CPA therapy. Taqman qRT-PCR data for the
denoted genes using TG and NTG populations from vehicle-
treated (V) control or CPA-treated tumors. Data represents
Mean6SEM (n$2).
Found at: doi:10.1371/journal.pone.0002428.s003 (6.61 MB TIF)
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